About Asacol (mesalamine)

Asacol (mesalamine) helps relieve ulcerative colitis symptoms including number of bowel movements and rectal bleeding as early as 3 weeks.* Asacol is the only sulfa-free 5-ASA medication indicated for both treatment of mild to moderate flare-ups of ulcerative colitis and maintenance of remission of ulcerative colitis.

Asacol (mesalamine) is Proven to Help Treat Flare-Ups

Asacol (mesalamine) has been proven to help treat mild to moderate flare-ups of ulcerative colitis.

In six-week clinical studies of flare-ups, Asacol helped many patients reduce their symptoms of ulcerative colitis, including number of bowel movements and rectal bleeding, for some as early as 3 weeks.*

Asacol is the #1 most dispensed oral 5-ASA medication. † In 2007 Asacol celebrated its 15th year as a therapy for UC.

Asacol (mesalamine) is Proven to Help Maintain Remission

In a six-month study, patients taking Asacol (mesalamine) at a maintenance dose were more likely to remain in remission as compared to those taking a placebo (sugar pill).

Ulcerative colitis rarely goes into permanent remission.

Lowest Average Out-of-Pocket Cost

Asacol offers the lowest average out-of-pocket cost versus other oral brand name mesalamine products.‡


*Individual results may vary.

† This information is an estimate derived from the use of information under license from IMS National Prescription Data for the 12 month period ending July 2008. IMS expressly reserves all rights, including rights of copying, distribution and republication. This statement does not imply superior efficacy or safety.

‡ SDI's Vector One®: Payer, for the 6 month period ending August 2008. Out-of-pocket cost is the portion of the prescription cost that the patient is required to pay. These data include patients who pay the entire cost of their prescription and those who receive coverage via private insurance, Medicaid, or Medicare. VA and mail order co-pays are not included. Lower out of pocket costs to patients do not necessarily reflect a cost savings to providers. Products that are subject of a price comparison are not known to have comparable efficacy and safety.